ACCURAY INC (ARAY) Stock Fundamental Analysis
NASDAQ:ARAY - Nasdaq - US0043971052 - Common Stock - Currency: USD
Overall ARAY gets a fundamental rating of 3 out of 10. We evaluated ARAY against 191 industry peers in the Health Care Equipment & Supplies industry. ARAY has a bad profitability rating. Also its financial health evaluation is rather negative. ARAY is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
ARAY had negative earnings in the past year.
In the past year ARAY has reported a negative cash flow from operations.
In the past 5 years ARAY reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: ARAY reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of ARAY (-0.91%) is better than 71.20% of its industry peers.
ARAY has a Return On Equity of -9.13%. This is in the better half of the industry: ARAY outperforms 68.06% of its industry peers.
ARAY has a Return On Invested Capital of 1.37%. This is in the better half of the industry: ARAY outperforms 69.63% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ARAY is significantly below the industry average of 7.68%.
The last Return On Invested Capital (1.37%) for ARAY is above the 3 year average (1.33%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.91% | ||
| ROE | -9.13% | ||
| ROIC | 1.37% |
ROA(3y)-2.13%
ROA(5y)-1.38%
ROE(3y)-20.59%
ROE(5y)-12.99%
ROIC(3y)1.33%
ROIC(5y)2.66%
1.3 Margins
Looking at the Operating Margin, with a value of 1.06%, ARAY is in the better half of the industry, outperforming 67.02% of the companies in the same industry.
ARAY's Operating Margin has improved in the last couple of years.
With a Gross Margin value of 31.75%, ARAY is not doing good in the industry: 73.82% of the companies in the same industry are doing better.
ARAY's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.06% | ||
| PM (TTM) | N/A | ||
| GM | 31.75% |
OM growth 3Y-50.12%
OM growth 5Y37.15%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.31%
GM growth 5Y-3.77%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ARAY is destroying value.
The number of shares outstanding for ARAY has been increased compared to 1 year ago.
Compared to 5 years ago, ARAY has more shares outstanding
The debt/assets ratio for ARAY has been reduced compared to a year ago.
2.2 Solvency
ARAY has an Altman-Z score of -0.01. This is a bad value and indicates that ARAY is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ARAY (-0.01) is comparable to the rest of the industry.
A Debt/Equity ratio of 3.51 is on the high side and indicates that ARAY has dependencies on debt financing.
ARAY has a Debt to Equity ratio of 3.51. This is amonst the worse of the industry: ARAY underperforms 85.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.51 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.01 |
ROIC/WACC0.16
WACC8.77%
2.3 Liquidity
ARAY has a Current Ratio of 1.62. This is a normal value and indicates that ARAY is financially healthy and should not expect problems in meeting its short term obligations.
ARAY has a worse Current ratio (1.62) than 71.20% of its industry peers.
ARAY has a Quick Ratio of 1.62. This is a bad value and indicates that ARAY is not financially healthy enough and could expect problems in meeting its short term obligations.
ARAY has a worse Quick ratio (0.88) than 79.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.62 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
ARAY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.67%, which is quite impressive.
The Revenue has been growing slightly by 1.25% in the past year.
Measured over the past years, ARAY shows a small growth in Revenue. The Revenue has been growing by 1.29% on average per year.
EPS 1Y (TTM)66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%120%
Revenue 1Y (TTM)1.25%
Revenue growth 3Y4.06%
Revenue growth 5Y1.29%
Sales Q2Q%8.33%
3.2 Future
The Earnings Per Share is expected to grow by 48.50% on average over the next years. This is a very strong growth
ARAY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.81% yearly.
EPS Next Y96.81%
EPS Next 2Y63.38%
EPS Next 3Y48.5%
EPS Next 5YN/A
Revenue Next Year7.96%
Revenue Next 2Y6.48%
Revenue Next 3Y5.81%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
ARAY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 13.49, which indicates a correct valuation of ARAY.
85.86% of the companies in the same industry are more expensive than ARAY, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 21.32. ARAY is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 13.49 |
4.2 Price Multiples
ARAY's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. ARAY is cheaper than 72.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 24.33 |
4.3 Compensation for Growth
ARAY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ARAY's earnings are expected to grow with 48.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y63.38%
EPS Next 3Y48.5%
5. Dividend
5.1 Amount
ARAY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:ARAY (4/21/2025, 2:29:43 PM)
1.445
-0.03 (-2.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners61.15%
Inst Owner Change-0.03%
Ins Owners2.15%
Ins Owner Change-3.01%
Market Cap148.59M
Analysts86
Price Target6.25 (332.53%)
Short Float %4.29%
Short Ratio5.86
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)101.87%
Min EPS beat(2)25.3%
Max EPS beat(2)178.43%
EPS beat(4)3
Avg EPS beat(4)-39.98%
Min EPS beat(4)-370.59%
Max EPS beat(4)178.43%
EPS beat(8)5
Avg EPS beat(8)-53.11%
EPS beat(12)8
Avg EPS beat(12)-37.96%
EPS beat(16)11
Avg EPS beat(16)-20.29%
Revenue beat(2)2
Avg Revenue beat(2)2.63%
Min Revenue beat(2)2.05%
Max Revenue beat(2)3.2%
Revenue beat(4)3
Avg Revenue beat(4)0.21%
Min Revenue beat(4)-12.76%
Max Revenue beat(4)8.35%
Revenue beat(8)5
Avg Revenue beat(8)0.55%
Revenue beat(12)7
Avg Revenue beat(12)0.3%
Revenue beat(16)11
Avg Revenue beat(16)2.13%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-900%
EPS NY rev (1m)0%
EPS NY rev (3m)66.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.22%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.3%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 13.49 | ||
| P/S | 0.33 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.1 | ||
| P/tB | N/A | ||
| EV/EBITDA | 24.33 |
EPS(TTM)-0.05
EYN/A
EPS(NY)0.11
Fwd EY7.41%
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS4.41
BVpS0.47
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.91% | ||
| ROE | -9.13% | ||
| ROCE | 1.74% | ||
| ROIC | 1.37% | ||
| ROICexc | 1.77% | ||
| ROICexgc | 2.43% | ||
| OM | 1.06% | ||
| PM (TTM) | N/A | ||
| GM | 31.75% | ||
| FCFM | N/A |
ROA(3y)-2.13%
ROA(5y)-1.38%
ROE(3y)-20.59%
ROE(5y)-12.99%
ROIC(3y)1.33%
ROIC(5y)2.66%
ROICexc(3y)1.95%
ROICexc(5y)4.2%
ROICexgc(3y)2.85%
ROICexgc(5y)6.2%
ROCE(3y)1.69%
ROCE(5y)3.37%
ROICexcg growth 3Y-52.47%
ROICexcg growth 5Y31.25%
ROICexc growth 3Y-51.1%
ROICexc growth 5Y33.71%
OM growth 3Y-50.12%
OM growth 5Y37.15%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.31%
GM growth 5Y-3.77%
F-Score5
Asset Turnover0.95
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.51 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 15.41 | ||
| Cap/Depr | 53.48% | ||
| Cap/Sales | 0.72% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.62 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | -0.01 |
F-Score5
WACC8.77%
ROIC/WACC0.16
Cap/Depr(3y)142.19%
Cap/Depr(5y)102.47%
Cap/Sales(3y)1.58%
Cap/Sales(5y)1.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%120%
EPS Next Y96.81%
EPS Next 2Y63.38%
EPS Next 3Y48.5%
EPS Next 5YN/A
Revenue 1Y (TTM)1.25%
Revenue growth 3Y4.06%
Revenue growth 5Y1.29%
Sales Q2Q%8.33%
Revenue Next Year7.96%
Revenue Next 2Y6.48%
Revenue Next 3Y5.81%
Revenue Next 5YN/A
EBIT growth 1Y82.59%
EBIT growth 3Y-48.1%
EBIT growth 5Y38.92%
EBIT Next Year8674.21%
EBIT Next 3Y444.8%
EBIT Next 5YN/A
FCF growth 1Y85.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y91.63%
OCF growth 3YN/A
OCF growth 5YN/A